抗心律失常药物来预防心脏突发死亡:有没有前进的道路?
Iris Zieler1, Michael J Curtis1, Louise M Hesketh1
1School of Cardiovascular and Metabolic Medicine & Sciences, Faculty of Life Sciences & Medicine, King's College London, Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK.
Pharmacology & therapeutics
|February 28, 2026
概括
突然心脏死亡 (SCD) 的预防面临挑战,原因是不有效的抗心律失常药物和缺乏低风险患者的试验. 未来的发展需要更安全的,针对疾病的选择性疗法来降低死亡率.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医学研究 医学研究
背景情况:
- 突然心脏病死亡 (SCD) 占全球15-20%的死亡人数,主要是由于冠心病 (CHD) 的心室节律失常.
- 现有的抗心律失常药物已显示出有限的疗效和显著的副作用,阻碍了它们的广泛使用.
- 大部分SCD发生在没有被诊断为CHD的低风险个体中,由于安全问题,该群体在临床试验中代表性不足.
研究的目的:
- 在抗心律失常药物开发的背景下,审查目前SCD预防策略.
- 分析过去抗心律不良药失败对临床实践和研究的影响.
- 探索未来抗节律失常药物开发的新方法,重点关注疾病选择性向.
主要方法:
- 对抗心律失常药物试验和SCD预防策略的文献综述.
- 分析导致抗心律失常药物无效和不良事件的因素.
- 讨论新发现及其在开发新疗法的潜在应用.
主要成果:
- 大多数抗心律失常药物试验未能显示出显著的益处或显示出不可接受的副作用.
- 目前的抗心律失常药物开发还没有为SCD带来普遍安全和有效的治疗方法.
- 对于适用于广泛应用的抗节律失常药物,特别是低风险人群,有极大需求.
结论:
- 过去的抗心律失败需要重新评估开发策略.
- 未来的抗心律失常药物开发应该优先考虑安全性和疾病特异性机制.
- 一种专注于疾病选择性向的新方法有望改善SCD预防.
相关概念视频
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
3.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.8K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.4K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.4K
01:25Dysrhythmias VI: Management of Dysrhythmias
545
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
545
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K